Return the favour: South Korea looks to U.S. for COVID-19 vaccine aid

Published 2021-04-21, 01:29 a/m
© Reuters. South Korean Foreign Minister Chung Eui-yong and Russian Foreign Minister Sergei Lavrov at the Foreign Ministry in Seoul
PFE
-
AZN
-

By Sangmi Cha

SEOUL (Reuters) - South Korea's foreign minister said on Wednesday he hopes the United States will help Seoul address its COVID-19 vaccine shortage as a return in favour of test kits and masks it sent to Washington earlier in the pandemic.

The request comes as the South Korean government has come under fire from local media for not doing enough to secure enough vaccines early. It has inoculated just 3% of its population due to tight global supply and limited access.

"We have been stressing to the U.S. that 'a friend in need is a friend indeed'," Chung Eui-yong told reporters at the Kwanhun Club, a representative association of journalists in South Korea.

He said South Korea had airlifted Washington a large volume of coronavirus test kits and face masks in the early stages of the pandemic "in the spirit of the special South Korea-U.S. alliance," even as domestic supply was very tight.

"We are hoping that the U.S. will help us out with the challenges we are facing with the vaccines, based on the solidarity we demonstrated last year."

Chung said the two countries were in talks and raised the potential contribution it can make to the global vaccine supply chain that the U.S. President Joe Biden is keen on.

Park Jin, an opposition party lawmaker, called for more aggressive vaccine diplomacy and urged the government to invoke its free trade agreement (FTA) with Washington to demand access to pharmaceutical products.

"The government needs to be more proactive... and The FTA provides us a legal base to demand (vaccines) as it stipulates the two countries' commitment to promoting the development of and facilitating access to pharmaceutical products," Park told Reuters.

The U.S. embassy in Seoul did not immediately reply to a Reuters' request for comment.

Around 1.77 million people in South Korea have had their first dose of AstraZeneca (NASDAQ:AZN) Plc or Pfizer (NYSE:PFE) vaccines. The low inoculation rate compares with a 40% vaccination rate in the United States, according to a Reuters data https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access.

© Reuters. South Korean Foreign Minister Chung Eui-yong and Russian Foreign Minister Sergei Lavrov at the Foreign Ministry in Seoul

South Korea reported 731 new COVID-19 cases on Tuesday, surging from 549 cases a day earlier, bringing the total number of confirmed cases to 115,926, with 1,806 deaths.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.